Abstract As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the company (GlaxoSmithKline) that manufactures mepolizumab (Nucala Ò ) to submit evidence on the clinical and cost effectiveness of mepolizumab for the treatment of severe eosinophilic asthma. The School of Health and Related Research Technology Appraisal Group (ScHARR-TAG) at the University of Sheffield was commissioned to act as the independent evidence review group (ERG). The ERG produced a review of the evidence for the clinical and cost effectiveness of mepolizumab as add-on to standard of care (SoC) compared with SoC and omalizumab, based upon the company's submission to NICE. The clinical-effectiveness evidence in the company's submission was based predominantly on three randomised controlled trials (DREAM, MENSA and SIRIUS) comparing add-on mepolizumab with placebo plus SoC. The relevant population was defined in terms of degree of asthma severity (four or more exacerbations in the previous year and/or dependency on maintenance oral corticosteroids [mOCS]) and degree of eosinophilia (a blood eosinophil count of C 300 cells/ll in the previous year) based on post hoc subgroup analyses of the pivotal trials. Other subpopulations were considered throughout the appraisal, defined by different eosinophil measurements, number of exacerbations and dependency (or lack thereof) on mOCS. Statistically significant reductions in clinically significant exacerbations were observed in patients receiving mepolizumab compared with SoC meta-analysed across MENSA and DREAM in the modified intention-totreat (ITT) population (rate ratio [RR] 0.51; 95% confidence interval [CI] 0.42-0.62) as well as in the relevant population (RR 0.47; 95% CI 0.36-0.62). In terms of quality of life, differences on the St. George's Respiratory Questionnaire in MENSA for add-on subcutaneous mepolizumab 100 mg vs. placebo were 7 and 7.5 units in the modified ITT and relevant populations, respectively. A number of issues in the clinical evidence base warrant caution in its interpretation. The ERG noted that the definition of SoC used in the trials differed from that in clinical practice, where patients with severe uncontrolled asthma start treatment with a mOCS. The company's economic post-consultation analysis incorporating a confidential patient access scheme (PAS) estimated that the incremental cost-effectiveness ratio (ICER) for add-on mepolizumab compared with SoC was £27,418 per quality-adjusted lifeyear (QALY) gained in the relevant population if patients stopped mepolizumab after 1 year unless (1) the number of exacerbations decreased at least 50% or (2) a reduction in corticosteroids dose was achieved whilst maintaining asthma control. The ERG applied an age adjustment to all utilities and corrected the post-continuation assessment utilities, which resulted in an ICER for add-on mepolizumab compared with SoC of £29,163 per QALY gained. The ERG noted that this ICER was not robust for patients who continued treatment due to a corticosteroid dose reduction where exacerbations had decreased by less than
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Key Points for Decision Makers
Add-on mepolizumab resulted in clinically and statistically significant reductions in asthma-related exacerbation rates and an improvement in healthrelated quality of life.
The cost effectiveness of mepolizumab compared with maintenance oral corticosteroids (mOCS) or in patients receiving mOCS is uncertain due to difficulties capturing the disutilities and costs associated with long-term mOCS use.
The appraisal committee concluded that the comparison between omalizumab and mepolizumab was not clinically relevant, since the two drugs were associated with different pathways and different populations.
The UK National Institute for Health and Care Excellence (NICE) recommended mepolizumab as an option for treating severe refractory eosinophilic asthma in adults with a blood eosinophil count of C 300 cells/ll in the previous year as well as four or more exacerbations in the previous year and/or dependency on mOCS, if the company provided the drug with the discount agreed in the patient access scheme. At 12 months, treatment should be continued only if the number of exacerbations is reduced by at least 50% or a clinically significant reduction in mOCS use is achieved while maintaining or improving asthma control.
Introduction
The National Institute for Health and Care Excellence (NICE) is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health in priority areas with significant impact. Health technologies must be shown to be clinically effective and to represent a costeffective use of national health service (NHS) resources in order for NICE to recommend their use within the NHS in England. The NICE single technology appraisal (STA) process usually covers new single health technologies within a single indication, soon after the UK market authorisation [1] . Within the STA process, the company provides NICE with a written submission alongside a mathematical model that summarises the company's estimates of the clinical and cost effectiveness of the technology. This submission is reviewed by an external organisation independent of NICE, the evidence review group (ERG), which consults with clinical specialists and produces a report. The NICE appraisal committee (AC) considers the company's submission, the ERG report and testimony from experts and other stakeholders, then formulates preliminary guidance, the appraisal consultation document (ACD), which indicates the initial decision of the AC regarding the recommendation (or not) of the technology. Stakeholders are then invited to comment on the submitted evidence and the ACD, after which a further ACD may be produced or a final appraisal determination (FAD) issued, which is open to appeal. An ACD is not produced when the technology is recommended within its full marketing authorisation, in which case, an FAD is produced directly.
This paper presents a summary of the ERG report [2] for the STA of mepolizumab for treating severe eosinophilic asthma and a summary of the subsequent development of the NICE guidance for the use of this drug in England. Full details of all relevant appraisal documents (including the appraisal scope, ERG report, company and consultee submissions, FAD and comments from consultees) can be found on the NICE website [3] .
The Decision Problem

Population (Severe Eosinophilic Asthma)
Asthma is a broad condition characterised by inflammation of the airways leading to reversible (and in some cases, irreversible [4] ) airway obstruction. Asthma symptoms include wheezing, chest tightness, cough and shortness of breath, and exacerbation (worsening) of symptoms can lead to hospitalisation and death. It is estimated that approximately 5.4 million people in England and Wales currently receive treatment for asthma [3] . Asthma varies in its severity but in most cases can be controlled with a combination of medications, which in the UK are administered in a step-wise manner (steps 1-5, with 1 being the lowest step) until control is reached, according to the British Thoracic Society (BTS)/Scottish Intercollegiate Guidelines Network (SIGN) guidelines [5] . The level of treatment required is also a measure of the severity of the condition.
The American Thoracic Society (ATS)/European Respiratory Society (ERS) Task Force defines severe asthma as ''asthma that requires treatment with high-dose inhaled corticosteroids (ICS) plus a second controller and/or systemic corticosteroids to prevent it from becoming 'uncontrolled' or that remains 'uncontrolled' despite this therapy'' [6] . These patients experience frequent exacerbations, despite controller medications, and have a decreased quality of life due to uncontrolled symptoms and treatment side effects, as many take oral corticosteroids long term. The impact of exacerbations on patients varies, with some just requiring systemic corticosteroids and others a hospital stay; ultimately, some patients die from an asthma exacerbation. There were 1242 asthma-related deaths in the UK in 2012. Severe asthmatics were found to account for 39% of deaths from asthma [7] , and the company (GlaxoSmithKline [GSK]) argued that, as severe asthmatics are only a small proportion of the total asthma population (5-10%), mortality is still ''an issue'' for this population.
Eosinophilic asthma is a distinct phenotype of asthma characterised by tissue and sputum eosinophilia (high levels of a type of white blood cell called eosinophils), a thickening of the basement membrane and, often, responsiveness to corticosteroids [8] . It can be present in mild, moderate or severe asthma [8] . However, it is associated with more severe disease, late onset, atopy and steroid refractoriness. The diagnosis of eosinophilic asthma is problematic in clinical practice. Induced sputum eosinophil levels of 2% [8] are commonly interpreted as indicating eosinophilic disease; however, this test is impracticable in routine care. Alternatives include peripheral blood eosinophil counts and fractional exhaled nitric oxide (FeNO), serum immunoglobulin E (IgE) and periostin levels. However, a recent US review [8] reported that these have limited diagnostic accuracy: levels of blood eosinophils [ 300 cells/ll had a positive predictive value of only 50% in identifying an eosinophilic asthma phenotype (defined as sputum eosinophils of [ 2%), serum IgE had no correlation with eosinophilia [9] , studies relating to FeNO appeared inconsistent [10] [11] [12] and the diagnostic utility of periostin was promising but as yet undetermined.
Despite only moderate diagnostic accuracy being reported for blood eosinophils in the literature, the test is used in clinical practice to monitor disease [5] . There is no national or international consensus on how to interpret such tests; however, clinical advisors to the ERG stated that a level of C 300 cells/ll in the previous 12 months is a commonly used cut-off.
Intervention
Mepolizumab (Nucala Ò , GSK) is a humanised anti-interleukin 5 monoclonal antibody (IgG1, kappa). Mepolizumab is indicated as an add-on treatment to standard of care (SoC) for severe refractory eosinophilic asthma in adult patients [13] . The licensed dose is 100 mg administered subcutaneously every 4 weeks, with the company assuming this will be undertaken by a specialist asthma nurse. The summary of product characteristics states that the need for continued therapy should be considered at least annually as determined by physician assessment of the patient's disease severity and level of control of exacerbations. A confidential patient access scheme (PAS) representing a simple discount on list price is in place for mepolizumab.
Comparators
NICE issued a final scope to appraise the clinical and cost effectiveness of mepolizumab, within its licensed indication, for the treatment of severe eosinophilic asthma. The main comparator was SoC, which, for patients with severe asthma, includes the use of high-dose ICS and other controllers, such as long-acting b-agonists, leukotriene antagonists or theophyllines, and finally daily oral corticosteroids (OCS) at the lowest possible dose to achieve adequate control. For people with severe persistent allergic IgE-mediated eosinophilic asthma, the intervention was also compared with omalizumab (brand name Xolair Ò ), a drug recommended by NICE for patients with severe IgE-mediated asthma who ''need continuous or frequent treatment with oral corticosteroids.'' The marketing authorisation of omalizumab states that 16 weeks after the start of treatment, physicians should assess the effectiveness of the treatment and should continue the treatment only in patients whose asthma has markedly improved. A confidential PAS is also in place for omalizumab.
The Independent Evidence Review Group (ERG) Review
The company provided a submission to NICE on the use of mepolizumab for the treatment of patients with severe refractory eosinophilic asthma. In accordance with the process for STAs, the ERG and NICE had the opportunity to seek clarification on specific points in the company's submission, in response to which the company provided additional information. The ERG also modified the company's decision analytic model to produce an ERG base case and to assess the impact of alternative parameter values and assumptions on the model results. The evidence presented in the company's submission and the ERG's review of that evidence is summarised here.
Clinical Evidence Provided by the Company
Pivotal Trials
The clinical-effectiveness evidence in the company's submission was based predominantly on three randomised controlled trials (RCTs) comparing mepolizumab, as addon to SoC, with placebo plus SoC in patients with severe eosinophilic asthma. Two trials (DREAM [14] and MENSA [15] ) had a primary endpoint of reduction in exacerbations, whereas one (SIRIUS [16] ) enrolled patients receiving maintenance oral corticosteroids (mOCS) and had a primary endpoint of reduction in OCS use. In addition, data from two open-label extension studies (COS-MOS [17] and COLUMBA [18] ) enrolling patients from the three RCTs were also included. Mepolizumab was provided at various doses within the trials; the doses considered here include the licensed subcutaneous dose of 100 mg and the intravenous dose of 75 mg, which is considered to be clinically equivalent to 100 mg delivered subcutaneously [19] .
Key Sub-Populations
Effectiveness and cost effectiveness were assessed for the following post hoc subgroups of patients from the pivotal trials:
• Intention-to-treat (ITT) population: all trial patients who were randomised and received at least one dose of study medication (strictly a modified ITT population).
• Company-proposed population: adult patients with severe refractory eosinophilic asthma with a blood eosinophil count of C 150 cells/ll at initiation of treatment and four or more exacerbations in the previous year and/or dependency on mOCS (regardless of exacerbations in previous year).
• Company-proposed restricted population: adult patients with severe refractory eosinophilic asthma with a blood eosinophil count of C 150 cells/ll at initiation of treatment and four or more exacerbations in the previous year.
• mOCS users with fewer than four exacerbations (denoted ''stable mOCS'' by the ERG): adult patients with severe refractory eosinophilic asthma with a blood eosinophil count of C 150 cells/ll at initiation of treatment and dependency on mOCS but fewer than four exacerbations in the previous year. This constitutes the patients in the company-proposed population who were not within the proposed restricted population. The term ''stable'' is used for ease of reading and refers to having fewer than four exacerbations in the previous year.
• Committee-preferred population: adult patients with severe refractory eosinophilic asthma with a blood eosinophil count of C 300 cells/ll in the previous year and four or more exacerbations in the previous year and/or dependency on mOCS (regardless of exacerbations in the previous year).
The company's rationale for the proposed population was based on post hoc modelling and subgroup analyses of DREAM and MENSA, indicating a greater reduction in exacerbations for mepolizumab versus placebo for patients with (1) higher baseline blood eosinophils and (2) more previous exacerbations. In addition, the company included mOCS users with a blood eosinophil level of C 150 cells/ ll in the proposed population (regardless of previous exacerbations), claiming mOCS users are likely to be a severe group and that there are clinical benefits to reducing use of mOCS. The company also provided data for the proposed restricted population. The ERG requested analyses for the stable mOCS population, as the efficacy of mepolizumab in these patients is expected to be lower than in the proposed restricted population. The AC proposed an alternative population (termed committee-preferred population), modifying the eosinophil level threshold in the company-proposed population, after concluding that a blood eosinophil level of C 300 cells in the previous year was more clinically significant of high eosinophil levels than C 150 cells/ll at screening.
Key Clinical-Effectiveness Results
Clinically significant exacerbations were defined in all three trials as worsening of asthma requiring use of systemic corticosteroids (or double the maintenance dose) and/or hospitalisation and/or emergency department (ED) visits. The rate ratios (RRs) for clinically significant exacerbations for add-on mepolizumab versus placebo observed in MENSA, DREAM and SIRIUS are shown in Table 1 .
For exacerbations requiring hospitalisation, RRs for mepolizumab (subcutaneous 100 mg and intravenous 75 mg groups combined) versus placebo, meta-analysed across MENSA and DREAM, were 0.50 (95% confidence interval 
Steroid Reduction
The SIRIUS trial had a primary endpoint of percentage reduction in OCS dose whilst maintaining asthma control. Odds ratios (ORs) for mepolizumab versus placebo, analysed using a proportional odds model for the proportion achieving various categories of reduction in OCS dose while maintaining asthma control were 2.39 (95% CI 1.25-4.56) for the ITT population, 1.81 (95% CI 0.86-3.79) for the proposed population, 2.75 (95% CI 0.72-10.59) for the proposed restricted population, and 3.51 (95% CI 1.69-7.25) for the committee-preferred population.
In terms of secondary outcomes in the committee-preferred population, the OCS dose was reduced by at least 50% in 57% of patients (mepolizumab) versus 28% (placebo), resulting in an OR of 3.36 (95% CI 1.5-7.52). A reduction in OCS dose to B 5 mg was observed in 56% of patients (mepolizumab) versus 28% (placebo), with an OR of 3.23 (95% CI 1.38-7.57). In addition, OCS use was stopped completely in 16% (mepolizumab) versus 4% (placebo), with an OR of 4.27 (95% CI 0.81-22.49). ORs were generally statistically significant in the modified ITT population. Results were slightly more favourable (in terms of magnitude of the point estimates) in the committeepreferred population and in the proposed restricted population than in the proposed population but were not statistically significant (p [ 0.05), though patient numbers were small.
Subgroup Analyses
The company used post hoc subgroup analyses to define the two proposed populations. Two options were considered for the eosinophil threshold: C 150/ll at screening or C 300/ll in the previous 12 months. Patients with C 150/ll at screening had a greater reduction in exacerbations for mepolizumab versus placebo than patients with \ 150/ll; this was not the case when the population was subgrouped using a threshold of C 300/ll in the previous 12 months. The company used this as the basis for focussing on patients with C 150/ll at screening. In terms of exacerbation history, subgroup analyses in DREAM and MENSA suggested that patients with more previous exacerbations had a greater reduction in exacerbations for mepolizumab versus placebo, though the findings were not conclusive. Potential issues relating to these sub-populations are discussed in Sect. 3.2.
Open-Label Extension Studies
The company provided data on two open-label, non-randomised, non-controlled extension studies enrolling patients completing the pivotal RCTs. Patients in COS-MOS (from MENSA and SIRIUS) either continued mepolizumab without interruption or switched from placebo to subcutaneous mepolizumab 100 mg for 52 weeks. Patients in COLUMBA (from DREAM) had a C 12-month treatment break and subsequently received subcutaneous mepolizumab 100 mg. COLUMBA is ongoing, and patients will receive mepolizumab for up to 3.5 years. The exacerbation rate per year in COLUMBA was 0.67; this was lower than the rate of 1.24 observed in the mepolizumab arm of the modified ITT population in DREAM.
The rate per year in COSMOS was 0.93; this was similar to the rate of 0.88 observed in the MENSA mepolizumab modified ITT population but higher than the rate of 0.68 observed in the SIRIUS trial.
Indirect Comparison of Mepolizumab vs. Omalizumab
The company undertook a network meta-analysis (NMA) of trials comparing mepolizumab or omalizumab and SoC. The main analysis included the ITT populations for both mepolizumab and omalizumab. Secondary analyses used full-trial populations for omalizumab (as it was not possible to obtain data on subgroups within the omalizumab trials) but a subgroup of patients from mepolizumab trials who were also eligible for omalizumab (eosinophilic and allergic asthma). Patients in the omalizumab trials in the main analysis were less severe (one or more exacerbation in the previous year) than in the mepolizumab trials (two or more exacerbations). The main analysis compared two double-blind mepolizumab RCTs (MENSA and DREAM) with two double-blind omalizumab RCTs (INNOVATE [20] and EXTRA [21] ). Two additional open-label RCTs of omalizumab were included in secondary analyses (Niven et al. [22] and EXALT [23] ). Based on a fixed-effect NMA undertaken by the company, mepolizumab gave a statistically significant reduction in clinically significant exacerbations compared with omalizumab (RR 0.664; 95% credible interval [CrI] 0.513-0.860). Mepolizumab was comparable to omalizumab for exacerbations requiring hospitalisation (RR 0.932; 95% CrI 0.350-2.490) and forced expiratory volume in 1 s (FEV 1 ; RR 0.645; 95% CrI -2.652 to 3.959). The company noted that results should be treated with caution since many trial patients were not eligible for both treatments, and study populations differed in severity. Given the heterogeneity between the trials included in the NMA, the ERG considered that a random-effects model would be more appropriate. A random-effects NMA undertaken by the company indicated that the reduction in exacerbations was not statistically significant (RR 0.664; 95% CrI 0.283-1.498). For exacerbations requiring hospitalisation, the treatment effect observed in the more restricted populations favoured omalizumab but was not statistically significant. The company concluded it was a reasonable assumption that mepolizumab would be at least as effective as omalizumab in patients eligible for both drugs.
Safety of Mepolizumab
In the RCTs, the risk of eczema, nasal congestion or dyspnoea was potentially higher with mepolizumab than with placebo. Adverse events (AEs) of special interest were systemic, hypersensitivity and injection-site reactions, cardiac events, infections and malignancies. Infusion-related reactions were higher for intravenous (but not subcutaneous) mepolizumab than for placebo, whereas injection-site reactions were higher for subcutaneous (but not intravenous) mepolizumab (8%) than for placebo (3%). Hypersensitivity reactions, infections and malignancies occurred at similar rates for mepolizumab and placebo, and there were no reports of anaphylaxis. Rates of all cardiac events were similar for mepolizumab and placebo, whereas rates of serious cardiac events were slightly higher for mepolizumab, though numbers were small. The incidence of the following serious AEs was higher with mepolizumab than with placebo: herpes zoster, hypertension, and myocardial ischaemia (all two vs. none, respectively). Few long-term safety data are available. In the RCTs and openlabel studies, 5-6% of patients receiving subcutaneous mepolizumab 100 mg developed anti-mepolizumab antibodies, which the company claimed did not discernibly impact upon the pharmacokinetics or pharmacodynamics of mepolizumab in the majority of patients. Neutralising antibodies were detected in one subject.
Critique of the Clinical Evidence and Interpretation
The systematic review process followed by the company was comprehensive, and the ERG was confident the searches were sufficient to identify all relevant studies of mepolizumab and omalizumab for inclusion in the review of clinical effectiveness. Although the ERG considered the evidence provided by the company to be generally of good methodological quality, a number of limitations and uncertainties in the evidence base warranted caution in its interpretation.
Limitations of the Trials
Patients were excluded from SIRIUS if they were unable to achieve a stable dose of OCS, which may not reflect clinical practice. Trial durations were relatively short (24-52 weeks). The primary outcome in DREAM and MENSA (clinically significant exacerbations) was a composite outcome including the requirement for systemic OCS (or double maintenance dose) and/or hospitalisation and/or ED visits.
Statistical Justification for the Sub-Populations
The post hoc subgroup and modelling analyses used to justify the company's proposed populations should be interpreted with caution. Multivariate modelling of DREAM data showed that patients with a blood eosinophil count C 150 cells/ll at screening had a C 30% reduction in rate of exacerbations for mepolizumab versus placebo; however, the uncertainty associated with the predicted rate reduction is not clear. The blood eosinophil threshold giving a 30% reduction in exacerbations varies between DREAM and MENSA and by number of previous exacerbations. The company's submission compares two options for a blood eosinophil threshold: C 150/ll at screening or C 300/ll in the previous 12 months.
Clinical Validity of Sub-Populations
The company claimed that the thresholds for eosinophil level and previous exacerbations were clinically plausible and practical to implement according to severe asthma specialists. In terms of eosinophil level, the European Medicines Agency concluded that eosinophil levels were not sufficiently predictive to justify a specific cut-off within their marketing authorisation. The ERG believed that the blood eosinophil count of C 150 cells/ll at screening was not a valid criterion to find a population in which mepolizumab is more effective in the medium and long term for two reasons: (1) 150/ll is, according to clinicians, within the normal range and (2) eosinophil levels can fluctuate. Given the uncertainties around the subgroup analyses and that a threshold of C 300 cells/ll in the previous 12 months was considered by clinicians and the committee to be more clinically relevant than C 150/ll at screening, the former was used in the definition of the committeepreferred population. Clinical advisors to the ERG considered that a threshold of four or more previous exacerbations was clinically appropriate and consistent with NICE guidance for omalizumab, which restricts the use of the drug to people requiring continuous or frequent treatment with oral corticosteroids (four or more courses in the previous year).
Evaluation of the Indirect Comparison
The indirect comparison methods appeared broadly appropriate. However, the ERG considered that the results of the random-effects model provided a more appropriate (and more conservative) estimate than those of the fixedeffects model given the heterogeneity between trials. The company further acknowledged that the results should be treated with caution since only a small proportion of patients in the mepolizumab and omalizumab trials were eligible for both treatments, and study populations differed in terms of severity.
Cost-Effectiveness Evidence
The company conducted a systematic review on the cost effectiveness of interventions for the treatment of severe eosinophilic asthma with mepolizumab but found no suitable studies. Therefore, the company developed a de novo economic model, implemented in Microsoft Ò Excel, to estimate the cost effectiveness of add-on mepolizumab compared with SoC and omalizumab.
The model employed a Markov cohort simulation approach. The perspective was that of the NHS. The starting age of the cohort was set at 50.1 years and the cycle length to 4 weeks; a lifetime time horizon was used. A discount rate of 3.5% per annum was used for both costs and utilities. The model included four states: (1) on-treatment before continuation assessment, (2) on-treatment after continuation assessment, (3) off-treatment and (4) death. All patients receiving mepolizumab or omalizumab treatment entered the model in the 'on-treatment before continuation assessment' state until the continuation assessment. After continuation assessment, patients transitioned either to 'on-treatment after continuation assessment' or 'off-treatment' depending on whether or not they met the continuation criteria: patients receiving mepolizumab continued with treatment unless the exacerbation rate worsened compared with the previous. Patients in the 'ontreatment after continuation assessment' state transitioned to the 'off-treatment' state when they discontinued treatment. Treatment discontinuation happened either due to natural attrition or by reaching the end of the treatment duration, which in the base case was assumed to be 10 years. All patients receiving SoC entered the model in the 'off-treatment' state. During any cycle, patients could transition from any of the alive states to death as a consequence of either asthma-related mortality (ARM) following an exacerbation or due to other causes.
The effectiveness of mepolizumab was reflected in reduced exacerbation rates and improved health-related quality of life (HRQoL). All exacerbation rates were initially calculated from the MENSA trial for both arms, mepolizumab and SoC. Different exacerbation rates were used before and after the continuation assessment to reflect the lower exacerbation rates of responders. The exacerbation rate for patients continuing with mepolizumab after the continuation assessment was assumed to be equal to that observed in patients meeting the continuation criteria during MENSA. The exacerbation rate for patients who discontinued mepolizumab was assumed to increase to that of patients receiving SoC.
The company's model assumed that ARM occurred only following a clinically significant exacerbation. In the basecase analysis, the mortality rates after clinically significant exacerbations were based on two sources: Watson et al. [24] and the National Review of Asthma Deaths (NRAD) report [7] . The company assumed that the deaths reported in Watson et al. [24] were those happening in hospital, which according to the NRAD report only account for 30% of asthma-related deaths. Therefore, the total number of deaths was assumed to be 100/30 times greater than those reported in Watson et al. [24] . The probability of death after hospitalisation according to Watson et al. [24] is 0.0038 for people aged 18-44 years and 0.0248 for people aged C 45 years. After consultation, the company undertook a retrospective cohort analysis using the same database as that used to inform Watson et al. [24] (the CHKS database) but applying the age stratification by Roberts et al. [32] : 45-54, 55-64 and C 65 years.
Utility values were obtained from two sources. EuroQol-5 Dimensions (EQ-5D) scores were captured at 4-weekly intervals in the DREAM trial. However, the MENSA and SIRIUS trials used the SGRQ. The base case used EQ-5D scores mapped from the SGRQ scores measured in the MENSA trial instead of the direct EQ-5D data captured within DREAM. The mapping from SGRQ scores to EQ-5D scores was performed using an algorithm proposed by Starkie et al. [25] to predict EQ-5D utility from the SGRQ in subjects with chronic obstructive pulmonary disease (COPD). The company justified the use of SGRQ-mapped scores, claiming ''EQ-5D did not capture the granularity in HRQoL of people with severe asthma.'' Similar to exacerbation rates, the company used different utility values before and after continuation assessment to reflect the higher HRQoL of responders. The utility value for patients receiving mepolizumab until continuation assessment was calculated based on all patients, whereas the utility value for patients continuing with mepolizumab after continuation assessment was calculated based solely on the patients meeting the continuation criteria. The utility value for patients discontinuing mepolizumab after continuation assessment was assumed to drop to that of patients receiving SoC. During consultation, the company revealed there was a baseline imbalance on the average EQ-5D values between patients receiving mepolizumab and those receiving SoC and presented baseline-adjusted utility values. Exacerbations were assumed to have an impact on patients' HRQoL. The disutility values and their duration were based on a study by Lloyd et al. [26] . However, for the duration of disutilities, the company accepted after consultation to use the midpoint between the average exacerbation durations as measured in MENSA and the duration of the Lloyd et al. [26] study, as explained in Sect.
3.4.
As explained in Sect. 3.1, the company conducted an NMA to calculate the exacerbation RRs for mepolizumab and omalizumab compared with SoC. The resulting mean exacerbation RRs compared with SoC were 0.496 for mepolizumab and 0.746 for omalizumab. These RRs were applied only to the period before continuation assessment because of the differences in the continuation criteria between the two treatments: patients continued with mepolizumab unless the exacerbation rate worsened, whereas patients receiving omalizumab continued only if they achieved a score of good or excellent in the global evaluation of treatment effectiveness (GETE). After continuation assessment, the same exacerbation rate as used in the base case was used for mepolizumab, whereas the exacerbation rate observed in omalizumab responders during the INNOVATE trial [20] (0.373) was used for omalizumab.
The cost of mepolizumab used in the model included the PAS proposed by the company. The list price reported in the British National Formulary (BNF) [27] was used for omalizumab, as directed by NICE, although a commercialin-confidence PAS is in place. Instead of using the cost of the omalizumab treatment used in the recent omalizumab multiple technology assessment (MTA) [28] , the company undertook a study to estimate the cost of omalizumab treatment in clinical practice. The calculation of the average cost of omalizumab treatment is not straightforward because the frequency and dosage of the injections depend on the patient's weight and serum IgE levels. The company-led study concluded that the annual cost of omalizumab treatment was considerably higher (£11,370) than that calculated based on the INNOVATE trial and used in the omalizumab MTA (£8056). Unit costs for administration and monitoring were taken from the Personal Social Services Research Unit (PSSRU) [29] and NHS reference costs 2013/2014 [30] , whereas drug costs for SoC were taken from the BNF [27] . Costs were updated when necessary to 2014 values using the health service cost index (hospital and community health services [HCHS]) [29] .
In their original base-case analysis, the company estimated that the probabilistic incremental cost-effectiveness ratio (ICER) for add-on mepolizumab versus SoC was £19,511 per quality-adjusted life year (QALY) gained in their proposed population and £15,478 per QALY gained in their proposed restricted population. As the appraisal progressed, the definition of the target population changed, as did the PAS offered by the company, the continuation criteria, ARM rates, exacerbation rates and utility values, based largely on the reasoning presented in Sect. 3.4. The final ICER presented by the company for add-on mepolizumab compared with SoC for the committee-preferred population and continuation criteria was £27,418 per QALY gained. All analyses in the company's submission used the PAS for mepolizumab.
Based on the list price for omalizumab, the company's analysis concluded that mepolizumab dominated omalizumab as it was estimated to be less expensive and more effective. Mepolizumab dominated omalizumab in all the sensitivity analyses undertaken by the company. The validity of these results is limited because of the PAS in place for omalizumab.
Critique of the Cost-Effectiveness Evidence and Interpretation
The mathematical model submitted by the company was conceptually reasonable and complete and had only a few minor implementation errors.
Continuation Criteria
The original continuation criteria proposed by the company (i.e. continue receiving treatment unless the exacerbation rate increases compared with the previous year) implied that a subgroup of patients could continue with treatment even when experiencing no improvement. The company argued that some patients could benefit from an OCS dose reduction while maintaining asthma control. The AC consequently proposed continuation criteria as follows: a reduction of at least 50% in exacerbation rate and/or a clinically significant reduction in mOCS dose while maintaining or improving asthma control. The ERG noted that the ICERs calculated in the appraisal only reflected the cost effectiveness of patients whose exacerbation rate was reduced at least 50%, since the effectiveness estimates were based on trials where an mOCS dose reduction was not allowed. The ERG noted that the ICER for mepolizumab versus SoC in patients whose mOCS dose is reduced but whose exacerbation rate was maintained was likely to be higher than that of patients whose exacerbation rate was reduced at least 50%. This is because an important part of the treatment benefit comes from exacerbation reduction.
Inclusion of Subjects Using Maintenance Oral Corticosteroids with Fewer than Four Exacerbations in the Proposed Population
The difference in the estimated ICERs per QALY gained between the proposed population and the proposed restricted population suggested the use of mepolizumab in mOCS users with fewer than four exacerbations may have a high ICER. In response to the ERG's clarification questions, the company undertook a scenario analysis for this sub-population that resulted in an ICER of £78,716 per QALY gained, based on the company's original analysis and original PAS price.
Exacerbation Rates After Continuation Assessment
The exacerbation rates used in the model were calculated by dividing the number of exacerbations by the number of person-years of exposure in the MENSA trial. Those for patients continuing treatment after continuation assessment were calculated based on the data from week 16 to the end of the trial (week 32) in patients who met the continuation criteria at the end of MENSA. This is not ideal for three reasons: (1) the future rates of asthma observed in patients who met the continuation criteria (which was a nonworsening of the exacerbation rate) are likely to be higher than those observed, due to regression to the mean; (2) the exacerbation rate was measured during a short period (16 weeks), which results in uncertainty; and (3) measurements may be subject to potential inaccuracy due to the seasonal nature of asthma exacerbations. The ERG proposed instead to use the exacerbation rates observed in the COSMOS open-label extension trial in patients who met the continuation criteria in MENSA and went on to participate in COSMOS. The AC agreed with this proposal, and the company provided the relevant rates from COS-MOS. The ERG also noted that patients receiving mepolizumab who did not meet the continuation criteria had, by definition, the most severe asthma and therefore it was not reasonable to assume they would go on to have the average exacerbation rate observed in SoC. The AC agreed, and the company provided the exacerbation rates of patients observed in COSMOS in patients who had failed the continuation criteria in MENSA, which were higher than those observed in SoC in MENSA.
Asthma-Related Mortality
The company used ARM rates reported by Watson et al. [24] and the relative rates of ARM outside of hospital reported in the NRAD report [7] . The ERG noted that Watson et al. [24] used a constant rate of ARM for those aged C 45 years. However, the age stratification in Roberts et al. [32] indicated that the rate of ARM was approximately six times higher in the group aged C 65 years than in the group aged 45-54 years. The ERG noted there was no evidence to indicate this proportion was not applicable to patients with severe asthma. Therefore, the ARM rate for those aged C 45 years in Watson et al. [24] was likely to overestimate mortality between the ages of 45 and 65 years and underestimate it above the age of 65 years. This, in turn, would overestimate the benefits of a reduction in ARM, as early deaths have a bigger impact than late deaths. After consultation, the company undertook a retrospective cohort analysis using the same database as that used to inform Watson et al. [24] but applying the age stratification of Roberts et al. [32] : 45-54, 55-64 and C 65 years. As expected, the mortality rate in those aged 45-54 years was much lower (0.0092) than in those aged C 65 years (0.0455). The ICERs for add-on mepolizumab compared with SoC as calculated by the company increased when using the ARM rates with the new age stratification instead of that in Watson et al. [24] .
Utility Values
The company claimed the EQ-5D suffered from a ceiling effect and poor sensitivity in severe asthma. Therefore, the company used an alternative instrument, the SGRQ, and mapped to the EQ-5D using an algorithm proposed by Starkie et al. [25] to predict EQ-5D utility from the SGRQ in subjects with COPD. The ERG noted that the extent to which the mappings obtained using data from COPD rather than asthma could influence the results was uncertain. Furthermore, if the mapping algorithm correctly predicted the EQ-5D scores of patients with severe asthma, then the mapping would not address the claimed deficiencies of the EQ-5D. The ERG believed that the directly measured EQ-5D values were preferable to mapped EQ-5D estimates, and the AC agreed. Therefore, directly measured EQ-5D values were used in the rest of the appraisal. In a similar way as with exacerbation rates, the company assumed that the utility value of patients failing to meet the continuation criteria and discontinuing mepolizumab would drop to that of the average of patients receiving SoC. The ERG noted that the subgroup of patients failing the continuation criteria was likely to be the most severe subgroup and calculated the adjusted utilities for this subgroup based on the average utility for patients receiving mepolizumab and the average utility of patients receiving mepolizumab who met the continuation criteria.
Duration of Disutility from Exacerbations
The company assumed that the disutilities reflecting the impact of exacerbations on HRQoL reported in Lloyd et al. [26] would last for 28 days, based on the length of the Lloyd et al. [26] study. The ERG considered that using the duration of the exacerbations as measured in MENSA would be more appropriate. The company then argued that the disutility due to an exacerbation could last longer than its measured length in terms of OCS burst or hospital stay. The ERG acknowledged the potential for the duration of the disutility from exacerbations to be underestimated using only the average length of exacerbations in MENSA. Consequently, the company and the ERG agreed that using the midpoint between the mean duration of exacerbations in MENSA and the length of the Lloyd et al. [26] study was a reasonable compromise.
Oral Corticosteroid Sparing
The company's submission included a scenario analysis that took into account the costs and consequences of longterm systemic OCS usage. This analysis had several limitations: (1) it used OCS-sparing data from the ITT population of SIRIUS instead of the company's proposed or committee-preferred populations; (2) it used OCS-sparing estimates from SIRIUS while using exacerbation reductions from MENSA; (3) the time horizon considered was 10 years instead of lifetime costs, and utility decrements from fractures (resulting from osteoporosis) were not considered; (4) some utility decrements estimated as chronic conditions were considered as one-off disutilities; and (5) the proportion of the cohort that was alive at each cycle was not considered when calculating the incidence of AEs, and nor were patients who experienced chronic disutilities from AEs and died accounted for. The company acknowledged and the ERG agreed that the company's analysis did not appropriately capture the long-term benefits of OCS reduction.
Comparison with Omalizumab
The ERG considered the cost of omalizumab used within the MTA to be more appropriate than that of the company's study because its use meant costs and efficacy data derived from the same source. The ERG noted that NICE guidance recommends omalizumab only for patients on ''continuous or frequent treatment with oral corticosteroids'' [28] . The ERG believed that omalizumab should be compared with mepolizumab in the population in which omalizumab is recommended. The company used the exacerbation RR of omalizumab for the ITT population (0.373) instead of that reported for the mOCS subgroup (0.293) [31] . Finally, the ERG believed that using a random-effects model to calculate the exacerbation RR for patients before continuation assessment was more appropriate for the NMA than for the fixed-effects model used by the company.
Additional Work Undertaken by the ERG
The ERG undertook additional analyses using assumptions that differed from those made by the company in their base case. These analyses informed the AC and led to new analyses by the company. The list of alternative assumptions used by the ERG that were incorporated into the company's revised base case is as follows:
1. Use of the exacerbation rates observed in the COSMOS open-label extension study for patients receiving mepolizumab after continuation assessment. 2. Use of directly measured EQ-5D scores instead of the scores mapped from SGRQ. 3. Use of alternative ARM rates: first, using the rates combining the data from Watson et al. [24] and Roberts et al. [32] and, after consultation, using those calculated in the company's retrospective cohort study. 4. Use of the duration of disutility due to exacerbations equal to the midpoint of the length of exacerbations measured in MENSA and the length of the Lloyd et al. [26] study.
The ERG applied the following changes to the company's revised base case:
1. Use of age-adjusted utilities, as per Ara and Wailoo [33] . 2. Use of the attrition rate calculated on the committeepreferred population instead of the ITT population. 3. Use of average age at start from the committeepreferred population (51.5 years) instead of the ITT population (50.1 years). 4. Use of the correct percentage of patients meeting the continuation criteria in the committee-preferred population (the company had made a minor error that was acknowledged upon clarification request).
After these changes were applied to the company's revised base case, the ICER for mepolizumab compared with SoC increased from £27,418 to £29,163 per QALY gained. These ICERs were calculated based on continuation criteria stating that patients receiving mepolizumab would discontinue treatment after 1 year unless their number of exacerbations reduced by at least 50% or their mOCS dose was reduced while maintaining asthma control. However, patients were not allowed to reduce their mOCS dose in the trials that served as an evidence source for treatment efficacy. Therefore, the ICER for patients who do not achieve a 50% reduction in the number of exacerbations but continue receiving treatment because of a reduction in mOCS dose while maintaining asthma control is uncertain. The ERG estimated the ICER of mepolizumab versus SoC for these patients to be £60,825 per QALY by assuming these patients would have the same reduction in exacerbations as that observed in the MENSA RCT in patients receiving SoC (50.4%). This ICER does not take into account the benefits of avoiding long-term mOCS side effects, but the ERG noted that doing so is unlikely to drive the ICER under the threshold of £30,000 per QALY.
The ERG undertook exploratory analyses assessing the impact of different continuation criteria, different average age at treatment start and a potential waning effect. The ICER for mepolizumab compared with SoC increased from £29,163 to £31,378 and to £31,895 per QALY when the continuation criterion threshold for reduction in exacerbations was lowered from 50 to 30 and 0%, respectively. The ERG argued that, if mepolizumab were to be recommended, the average age at treatment start would be lower than that observed in the trials because patients would start on mepolizumab soon after their asthma was uncontrolled in step 4 (high-dose ICS plus additional maintenance treatments and short courses of OCS). The ERG estimated that the ICER of mepolizumab would increase from £29,163 to £32,557 and to £39,761 per QALY if the average age at treatment initiation was 45 and 40 years, respectively, instead of the 51.5 years observed in the trial. The AC considered a hypothetical waning effect in the treatment efficacy. The company argued that there was no evidence of a waning effect and that the mechanism of action of the drug did not justify a waning effect. However, in the absence of long-term effectiveness data, the ERG presented results of exploratory analyses that showed that the ICER of add-on mepolizumab versus SoC would increase from £29,163 to £34,744 and to £43,429 per QALY if treatment effect was assumed to wane linearly until losing all its effect in 30 and 10 years, respectively.
Conclusions of the ERG Report
The evidence submitted by the company is consistent with the NICE scope for interventions, comparators and relevant outcomes. The ERG was satisfied that the final definition of the relevant population included the blood eosinophil count of C 300 cells/ll in the previous year instead of the C 150 cells/ll at screening. The criterion of four or more exacerbations in the previous year appeared more clinically robust than a dependency on mOCS.
The ERG noted that the AC shared its preference for using the exacerbation rates from the COSMOS extension study and that it adopted the adjustments in the exacerbation rates and utilities for non-responders and the mortality rates based on more accurate age stratification. However, the ERG noted that the ICERs used by the AC in its decision to recommend add-on mepolizumab were based on only part of the relevant population. The continuation criteria establish that patients who have not achieved a 50% reduction in the number of exacerbations can still continue with treatment if their dose of mOCS is reduced whilst maintaining asthma control. However, the trials in which the treatment effect was measured did not allow a reduction in mOCS dose. The ERG believes that the ICER for this subgroup is higher than that reflected in the FAD.
Key Methodological Issues
The best way to define the relevant population in terms of severity of asthma and degree of eosinophilia was unclear. The company defined severity of asthma in terms of number of exacerbations in the previous year and/or dependency on mOCS. The company argued that patients receiving mOCS were especially severe cases, regardless of the number of exacerbations. The ERG noted that mepolizumab was likely to be less cost effective in patients receiving mOCS who had fewer than four exacerbations in the previous year. The level of eosinophilia was defined by the company using a blood eosinophil count of C 150 cells/ll at screening. The ERG, advised by its clinical experts, argued against this criterion because blood eosinophil levels fluctuate over time and a blood eosinophil count of C 150 cells/ll is well within the normal range. Consequently, the AC preferred to use a blood eosinophil count of C 300 cells/ll in the previous year to define the relevant population.
The company's economic model was based on an analysis of responders and non-responders. The company assumed that non-responders would have a disease progression similar to those receiving SoC. However, the ERG pointed out that, if the responders are individuals with a better prognosis, then the non-responders would have a worse prognosis than the average patient in the control arm. The ERG consequently applied adjustments for the exacerbation rates and the utilities of non-responders.
The company tried to include the benefits of mOCS sparing in their model. It is well known that the long-term use of mOCS has important side effects. However, it is difficult to capture these side effects, as they affect the likelihood of a patient developing a myriad of conditions. The company included cataracts, myocardial infarction, peptic ulcer and osteoporosis in their analysis, but these are only a subset of the conditions affected by the long-term use of mOCS. In addition, estimating how a partial reduction of the mOCS dose affects the incidence of these side effects is complicated. Further research on this topic would be of high interest given the prevalence of OCS in current practice.
Finally, the continuation criteria included a condition that was not observed in the trials used to estimate treatment efficacy, i.e. the reduction in mOCS dose. In the absence of evidence on how the reduction of mOCS would affect the treatment effect in these trials, the ERG and the AC were forced to estimate the ICER for this subgroup based on other trials.
National Institute for Health and Care
Excellence Guidance
In December 2016, following three AC meetings, and on the basis of the evidence available (including verbal testimony of invited clinical experts and patient representatives), the AC produced guidance that add-on mepolizumab was recommended as an option for treating severe refractory eosinophilic asthma in adults only if the blood eosinophil count is C 300 cells/ll in the previous 12 months and the patient has had four or more exacerbations in the previous year or has been on mOCS over the previous 6 months. The AC established that mepolizumab should be discontinued unless the number of exacerbations was reduced by C 50% or a clinically significant reduction in mOCS use was achieved while maintaining or improving asthma control. The recommendation was conditional on the company providing mepolizumab with the agreed PAS.
Consideration of Clinical-and CostEffectiveness Issues Included in the Final Appraisal Determination
The full list of the issues considered by the AC can be found in the FAD [34] . The key issues are described in the following sections.
Current Clinical Management
The AC considered the current clinical management of severe eosinophilic asthma in England and noted that it follows guidelines from the BTS and SIGN. The clinical experts explained that the management of severe eosinophilic asthma lies within what was previously known as step 4 and step 5 of the superseded 2014 version of the BTS and SIGN guidelines. The current guidelines (2016) indicate that people having high-dose therapies (previously step 4) or continuous or frequent use of oral steroids (previously step 5) should be referred for specialist care. The AC understood that oral systemic corticosteroids are used either for short periods to manage an exacerbation or for longer periods as maintenance treatment when it is difficult to wean people off corticosteroids without an increase in exacerbations. The AC concluded that, in clinical practice in the NHS, people with severe refractory eosinophilic asthma who have adhered to an optimised standard treatment plan (that is high-dose therapies [previously step 4] or continuous or frequent use of oral corticosteroids [previously step 5]) might be offered mepolizumab by a specialist.
Uncertainties in the Clinical evidence
The AC concluded that the comparison of mepolizumab with omalizumab was neither clinically relevant nor methodologically robust and therefore did not consider this comparison further.
Uncertainties in the Economic Modelling
The AC noted that the ICER was higher when the age of onset of treatment was lower. The AC concluded there was some evidence to suggest that the age of onset of treatment was lower than the company's estimate and agreed to take this into account when making its decision. The committee recognised the challenges in modelling the benefits of reducing mOCS and therefore also a related continuation rule.
Conclusion
The NICE AC considered the ERG's ICER of £29,163 per QALY but acknowledged that the ICER would be (1) higher (£32,557 per QALY) if patients were younger (45 years) at treatment start than the mean age in the relevant subgroup in the trial (51.5 years) or (2) lower if the adverse effects associated with the long-term use of systemic corticosteroids were accounted for. The AC therefore concluded that mepolizumab, as an add-on to SoC, could be recommended as an option for treating severe refractory eosinophilic asthma in adults who had had four or more exacerbations in the previous year and/or dependency on mOCS, and a blood eosinophil count of C 300 cells/ll in the previous year, if patients discontinued treatment after a year unless a reduction in the number of exacerbations of at least 50% was achieved or systemic corticosteroids use was reduced while maintaining asthma control.
